Alzheimer’s drug prescribed ‘off-label’ for mild cognitive impairment could pose risk for some

Health + Behavior – UCLA

UCLA School of Nursing researchers found that people with a certain genetic variation who took donepezil for the condition had a faster cognitive decline than those who took a placebo.

Read More

click
tracking
Share
Share